Amgen Sees Plenty Of Interest In US Eylea Biosimilar, Buoyed By Strong Supply Chain

Retina Teams Deployed As Amgen Awaits News On Permanent Reimbursement Codes

All eyes are on Eylea, after Amgen said last week that it would launch the first US biosimilar in the face of ongoing litigation. The California-based player has spoken of its prospects in the wet-AMD space, including a desire to chart its own path amid supply shortages for Avastin.

Rocket_Launch
• Source: Shutterstock

More from Biosimilars

More from Generics Bulletin